HEALTH

ko
15 Members

Cards

Updated

COVID-19 Impact on Phototherapy Treatment in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Phototherapy Treatment in Healthcare Industry COVID-19 spread badly across the world with high number of cases reported in various countries of globe. COVID-19 has made very bad effect on daily lives as well as the global economy. Many health care companies have to face various complex challenges due to COVID-19. The first case of COVID-19 was reported in the city of Wuhan, China from where it spread in various countries and become pandemic for world. The pandemic situation has badly affected the health care companies and also become opportunity for some domestic companies. COVID-19 also affected the global phototherapy treatment market by influencing price of phototherapy treatment, demand and supply of phototherapy treatment and various strategic decisions taken by phototherapy treatment centres. The COVID-19 pandemic has resulted in the closure of many phototherapy units. Phototherapy is defined as medical treatment that involves exposure to fluorescent light bulbs or other sources of light such as halogen lights, light emitting diodes (LEDs) and sunlight to treat critical medical conditions. The phototherapy is also known as light therapy and heliotherapy. There are mainly two types of phototherapies: narrowband ultraviolet B (NB-UVB) light therapy and broadband ultraviolet B (BB-UVB). Narrowband ultraviolet B is the most commonly used phototherapy. It can be used to treat plaque or guttate psoriasis. Broadband ultraviolet B (BB-UVB) is an older form of phototherapy than NB-UVB. BB-UVB is the most effective for plaque psoriasis. Natus Medical Incorporated is one of the leading players of phototherapy treatment market. But there is decrease in revenue and gross profit of Natus Medical Incorporated in first quarter of 2020 as compared to the revenue and gross profit of company in first quarter of 2019. This shows the negative impact of COVID-19 on global phototherapy treatment market. PRICE IMPACT The spread of COVID-19 has negative impact on demand of phototherapy treatment. 50% of patients stopped arriving for the phototherapy treatment due to the fear of COVID-19 infection. The COVID-19 spread also lead to closure phototherapy unit across the globe. This closure also has negative impact on global phototherapy treatment market. Most of phototherapy units have increased their price for the generation of more profit. For instance, · The average price of UVB therapy is increased to USD 3,600 annual per patient cost is increased from USD 2,600 annual per patient cost. · The average cost for phototherapy for neonatal jaundice is between USD 3,000 to USD 5,000 is increased from USD 2,703. IMPACT ON DEMAND The COVID-19 pandemic has resulted in the closure of many phototherapy centers in the world especially in areas which are badly hit by the pandemic and areas where maintaining social distancing is difficult. Currently, there is no guidance on managing a phototherapy service or for resuming the service during pandemic. Because spread of COVID-19 risk varies with disease prevalence and because disease prevalence varies in different locations, the decision to resume phototherapy operations needs are based on local public health recommendations and for medical center based units in consultation with institution’s infection control units. Office phototherapy is generally not only an option. There is also an option of home phototherapy and judicial exposure to natural sunlight that should be weighted. This also affects the demand of phototherapy treatment. The effect of COVID-19 on phototherapy leads to decrease in demand of phototherapy for the treatment of various diseases. From March, more than 50% of patients stopped arriving to treatment due to the fear of COVID-19 infection. The chart shows that there is decrease in patients of phototherapy treatment due to spread of COVID-19 leading to the decrease in patients having negative impact on the market of phototherapy treatment. The major cause of decrease in patients going for phototherapy is the fear of COVID-19 infection. For instance, · The decrease in phototherapy treatment due to closure of many phototherapy units in the United States and around the world is because of the cause of closure of these phototherapy units spread of COVID-19. Especially the areas which are hardly hit by the pandemic or areas with difficulty in maintaining social distancing are affected more. · 50% of patients stopped arriving for phototherapy treatment due to fear of spread of COVID-19. This also shows the decrease in demand of phototherapy treatment. IMPACT ON SUPPLY As we know that COVID-19 spread badly across the world. Due to spread of COVID-19, lockdown have been imposed by government of various countries. There are restrictions on cross country transportation such as air freights ban across the globe. The transportation restrictions have direct impact on supply chain. This led to a decrease in supply of phototherapy treatment products. For instance, · Due to spread of COVID-19, there are restrictions in manufacturing and logistic activities have been suspended. An action plan has been proposed to tackle pandemic based disruptions for fulfilling the need of food grains, ingredients, medicine and other essential items. · The major suppliers of phototherapy treatment market are the U.S. and China. The global supply had begun responding to the U.S. - China tension and we can expect the disruption caused by COVID-19. Trades analytics also show China lost global export market share at an accelerated pace in 2019 as companies move to other countries. This disruption has direct effect on supply chain of phototherapy treatment products. STRATEGIC DECISIONS OF MANUFACTURERS Collaboration, agreements and strategic initiatives by market players such as Safaricom Foundation, Aesthetic Technology Ltd. among others in the phototherapy treatment market will help them to expand their product portfolio. This in turn will lead to increasing product sale and hence will enhance the overall company’s revenue. Major players of phototherapy treatment market companies are taking many decisions in order to cope up with the current scenario of COVID-19 pandemic. The companies engaged in manufacturing of products of phototherapy treatment are collaborating so as to accelerate the phototherapy treatment market growth. The companies have already taken several kinds of strategic initiatives in order to cope up with coronavirus situation. For instance, · In August 2019, Safaricom Foundation introduced an infant Sh8 million unit. It helps to enhance motherly and neo-natal healthcare services in the Lamu by installation of new incubators, newborn baby oxygen masks, a phototherapy unit and digital equipment. · In March 2019, Aesthetic Technology Ltd announced the launch of Tri-Wave MD and the Flex, designed for photodynamic therapy. The device supplies all three wavelengths at an enhanced optical power concurrently. · In February 2019, Natus Medical Incorporated issued a statement concerning the product recall commercialized during the period of 2011-2016 to March 21. The products sold after the period are upgraded and not affected with the potential discoloration associated with the defective products. CONCLUSION As the pandemic of COVID-19 resulted in several restrictions throughout the boarders, there is great economical unbalance throughout the world. Many segments have to face economic crises but still manufacturers of phototherapy treatment products are able to manage their stocks. Various manufacturers are continuously engaged in conducting clinical trials for demonstrating the safety and efficacy of phototherapy treatment along with this, they are constantly monitoring the supply chain so as to attain a lucrative growth. The rise in price is also beneficial for companies. They are gaining extra profit which is helping them to combat the negative effect on overall revenue for the growth of the global phototherapy treatment market.
Significant COVID-19 Impact on Home Healthcare in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Home Healthcare in Healthcare Industry The emergence of COVID-19 in March 2020 caught everyone off-guard. The deadly disease is caused by the SARS CoV-2 virus which spreads rapidly through close contact with the affected person. To put a halt to the extensive spread of the virus across the globe, a complete lockdown was announced. The traveling was stopped, borders were sealed and the trade was affected. The impact of COVID-19 was huge on the economy throughout the world. The markets in different domains were affected. Pharmaceuticals and medical technology was no exception. With the surging cases of COVID-19, people were advised to stay inside their homes as a part of the lockdown advisory. As suggested by World Health Organization (WHO), the elderly, people with existing co-morbidities children were strictly advised to not go outside their homes. People were switching to home healthcare systems to continue their treatment for existing medical conditions, thereby reducing the risk of going to the hospitals and healthcare clinics. Growing preference for home healthcare propelled the pharmaceutical and medical device manufacturing companies to develop devices that can be used in the comfort of the home and simultaneously provide continuous monitoring of pre-existing medical conditions such as diabetes. IMPACT ON THE PRICE As the pandemic emerged, the prices of healthcare services rose including hospital stays. The management of patients suffering from coronavirus, patients with pre-existing chronic illnesses, and the ones that require critical care cost lakhs of rupees per day. The prices skyrocketed during the pandemic in hospitals and medical centers. People looked for alternatives and preferred home care systems also minimizing the risk of catching the infection during hospital visitations. According to an article, the state governments in India capped the prices of hospital care ranging from 1 lakh to 3 lakh depending on the condition of the patient. On the contrary, the price range for homecare systems was calculated between 2,000-3,000 including the rentals of the essential medical equipment. If calculated for a 15-day service, the total came around just 75,000 inclusive of all the other miscellaneous services. The government was initiated to provide the benefit of subsidies or even give out grant support to the service providers. Even though healthcare in private settings became expensive, home healthcare systems came to a rescue to treat patients both with coronavirus and other critical conditions. IMPACT ON DEMAND As the lockdown was imposed worldwide, people were stuck at home and were required to continue with their ongoing treatments for the chronic illnesses at home only. As there was a special advisory for co-morbid conditions, the elderly, among others, demand for home healthcare shot up during the worldwide lockdown. Many companies providing such medical services observed a rise in the demand for their facilities, as the home care service providers were able to fill the void between the patients and the healthcare facilities. Along with that, smart devices that can continuously monitor various symptoms of numerous medical chronic illnesses were cleared by Food and Drug Administration (FDA) or were given Emergency Use Authorization (EUA) instead of COVID-19. For instance, · Portea Medical is a home care service provider in India, which has a very broad portfolio of services such as critical care, diabetes care, and lab testing medical equipment among others. According to a news article, MD and CEO of Portea Medical told that they observed a spurt in the demand for home care services as people were becoming more aware about their portfolio. She told the news tabloid that they saw a 60% rise in the demand for their services. The company also observed the surge in calls for remote consultation on their telemedicine helpline numbers. · Nightingale, a home care healthcare service division of Medwell Ventures Pvt. Ltd. also observed a rise in the demand for the health care services rose up by 20% in March 2020 when the lockdown had just been imposed. According to the CEO of the Medwell Ventures Pvt. Ltd., Post lockdown, the demand grew by 40% as states across India were opting for home quarantine. Thus, this became a statistical validation to the adoption of healthcare services at home. · Dexcom received the temporary use authorization by Health Canada of Dexcom G6 continuous glucose monitoring system for pregnant women suffering from Type 1, Type 2 or gestational devices. During the times of the pandemic, this has enabled them to monitor their glucose levels from comfort of their homes, thus reducing the risk of visiting hospitals and clinics. IMPACT ON SUPPLY As the world came to a standstill, travel and transportation services were stopped across the globe. The borders were sealed to contain the spread of the virus. The trade practices also faced major challenges during the pandemic. Consequently, The supply of pharmaceutical drugs and other medical devices their import, export, and local transportation were grave. As for people with chronic illnesses and critical patients, the timely delivery of medicines and medical care was paramount. Even for people with manageable chronic diseases the supplies of medicines were important. Many major market players kept a close on their supply chain management and took initiatives to keep with the demand among the end-users. For instance, · Abbott, a global company dealing with pharmaceutical drug and medical devices manufacturing came forward to manage and meet the demands of their customers. In order to maintain the continuous supply of their products, they kept a close eye on the level of their inventory of finished products. They also monitored the key components required in the making of their products. Along with that, they closely observed the raw materials that were critical in the making of the products at various levels across their manufacturing and supply chain thereby maintaining access to their products and technologies. STRATEGIES INTIATIATIVES BY MANUFACTURERS With the emergence of COVID-19, the safety of patients and employees working across the companies providing healthcare services became paramount. Many pharmaceutical and medical device manufacturing companies took initiatives in order to keep up with their operations and simultaneously following safety practices. Many major players in the market developed devices that helped the people with chronic illnesses to manage the symptoms and reduce the hospital visits. For instance, · Abbott, a pharmaceutical, medical devices and diagnostics company developed FreeStyle Libre 14 to monitor glucose levels for people suffering from diabetes at home. This medical device was made available in the hospitals to remotely monitor glucose levels along with the history of patients suffering from the disease and who can scan the levels by themselves · Abbott also partnered with American Diabetes Association along with some other organizations and donated approximately 25,000 FreeStyle Libre 14 day sensors in hospitals and other healthcare centers located in COVID-19 hotspots · Portea Medical, a home care service provider in India, collaborated with Delhi Government in order to set up and provide home isolation services for patient’s diagnosed coronavirus. As more than 80 percent patients are asymptomatic, they can be screened for home isolation. These patients were monitored remotely through an extensive monitoring system. They also submit medical reports tracking the conditions of their patients and also flagged of patients showing complications from the disease CONCLUSION With the mystery around the disease remains unsolved at many levels, the management of healthcare becomes imperative. The safety of the people is paramount and initiatives are being taken to get people through this unprecedented scenario. The demand for home care services has increased in the past year owing to the stay-at-home order to contain the infection. The trend is said to remain the same in the coming years as home care systems will bring down hospital visits and consultation costs along with providing services at the comfort of homes.
COVID-19 Impact on Aseptic Processing in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Aseptic Processing in Healthcare Industry Coronavirus (COVID-19) is a novel disease that originated in China, Wuhan, and then spread worldwide, due to which the World Health Organization has declared it a pandemic. The novel strain of coronavirus belongs to the same virus family that causes acute respiratory syndrome (SARS) and middle-east respiratory syndrome. Due to the rapid growth of the virus, lockdown and quarantine were the government initiatives to control the coronavirus. The COVID-19 pandemic has presented a humanitarian crisis, creating an extraordinary strain on society and affecting millions of people around the world. The speed and depth of disruption are creating unprecedented challenges for industries and are having a growing impact on the global economy. Beyond the negative impact of a traditional economic downturn due to factory closures, supply chain disruptions, movement restrictions, and social distancing requirements, the pandemic has put the medical industry at the center stage. In the current scenario, the healthcare industry is witnessing an unparalleled demand for diagnostic tests, personal protective equipment (PPE), medical ventilators, and other critical medical supplies. With the potentially high risk of infection, healthcare professionals (HCPs) are also facing significant challenges in providing specific and effective care (often remotely). Hospital systems are becoming overwhelmed with the rapidly increasing number of COVID-19 patients, which is weighing heavily on the pharmaceutical industry. While research efforts to find effective drugs against the novel coronavirus are picking up pace, it is imperative to tackle another big challenge – ensuring the safety and security of drugs and medical supplies until they reach the hands of those who need them the most. Many pharmaceutical companies remain focused on the immediate crisis – facilitating increased access to critical medicines and supporting HCPs, intensive care units (ICUs), clinics, hospitals and patients in new ways. Overall, the COVID-19 pandemic has caused massive disruptions to the healthcare system. While pharmaceutical companies recognise and are responding to immediate needs, pharmaceutical packaging companies are experiencing a new set of challenges. Prior to the pandemic, continued growth of the e-commerce industry in developing economies increased interest in sustainable materials and the integration of advanced technology were driving the growth of the pharmaceutical packaging industry. However, it needs to be ready for potential effects triggered by the COVID-19 crisis. On the other hand, growing anxiety about the transmission of COVID-19 through packaging surfaces is offering opportunities to capitalise on sterile formats. Aseptic processing is a processing technique wherein commercially, thermally sterilized liquid products like food or the pharmaceuticals are packaged into prior sterilized containers under aseptic conditions. This is done in order to produce shelf-stable products that would not require refrigeration. The processing majorly involves three steps: thermal sterilization of the product, sterilization of the packaging material, and conservation of sterility during packaging. Aseptic Processing Systems is a set of devices to maintain the sterility of the food products or the pharmaceutical items. They are packed within a sterile container that helps in maintaining its sterility efficiently. IMPACT ON DEMAND Owing to the global pandemic of COVID-19 the demand for the aseptic processing market has increased exponentially in the present scenario. Although we may not realize it, every single person in the world could be affected by the use of sterile products. This may include the use of needles to inject vaccines, administering lifesaving prescription drugs such as Insulin or Epinephrine or in a hopefully rare, but very real situation for 2020, the insertion of a ventilator tube to enable a patient suffering from COVID-19 to breathe. The rise in demand for eco-friendly packages is one of the prominent factors driving the growth of the global aseptic processing market. This is owing to the rising awareness regarding the environment and stringent regulations about the same. Also, manufacturers are keen on integrating aseptic processing with filling operations. This has facilitated the proliferation in the pharmaceutical industry for packaging numerous liquid drugs in sterilized containers. Consequently, there is an expansion in the reach of the global aseptic processing market. · The introduction of blow-fill-seal technology in aseptic processing has highly reduced the risk of microbial contamination. This technology is extensively used in liquid pharmaceutical applications and is gradually proliferating into biologics. The use of this technology simplifies the manufacturing process as it is highly automated. Moreover, the use of this technology in filling polymeric containers reduces the concerns of breakage or glass-particulate contamination. This development of this technology has increased the industry penetration of the global aseptic processing market, thus supporting its growth and this could increase the demand for the market. IMPACT ON SUPPLY The expansion in the food and beverages industry has led to a significant increase in the market’s growth. Aseptic processing is used in packaging dairy products, coconut water, and carbonated drinks among others. Along with this, the development of new aseptic processing technologies offering better results has expedited the aseptic processing market’s growth. Launching of new products and various acquisitions are expected to drive the aseptic processing market and is intended to impact the supply of the market positively. For instance: · Robotic integration is currently gaining ground in the primary packaging processes for RTU containers, such as syringes, vials, and cartridges. Robotic solutions supply pharmaceutical manufacturers with a faster, more cost-effective, and flexible method of filling different container formats via the same filling platform, responding to the growing demand for customized packaging, small batches, quick format, and product changeovers together with less user intervention during the filling process. Conventional systems do not adhere to the requirement for multiple formats, small-batch flexibility, or sizes and repeatable processes that decrease risk. Advances in technology have made robotics compatible with aseptic manufacturing, with complete tolerance to sterilizing agents and almost no particle generation. Robots provide flexibility, which is an advantage over traditional aseptic machinery. · The GENiSYS R from AST is a modular system that automates aseptic filling and the closing of vials, syringes, and cartridges. Formulated for small batch filling, the system uses robotics from Stäubli, a mechatronics solutions provider, to attain complete in-process control for applications involving drug manufacturing, compounding, cell and gene therapy development, personalized medicine, and cytotoxic drug processing. · Bosch has launched a new aseptic linear filling and sealing machine called FCL 3080 A. This machine offers enhanced efficiency and is used for packaging baby food and dairy. It reduces the risk of food contamination because of the presence of a small aseptic chamber that facilitates improved product control. Additionally, it can handle two different cup formats, thus enhancing the flexibility. This machine has served as a major breakthrough in the global aseptic processing market, thereby strengthening its growth. · Pran has started aseptically processing tomato pulp at its Barind Industrial Park in Rajshahi to attain a longer shelf life for enabling its export alongside grabbing a bigger share of processed tomato sales in the country. Pran, one of the country's leading food processors, has already been exporting tomato sauce and ketchup to 60 countries, including Malaysia, the United Arab Emirates, U.S., Italy and Sweden. · Cytiva has acquired Vanrx Pharmasystems, a Canadian maker of robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed. Vanrx's flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators. These standardized, flexible systems provide a fast and certain path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals. CONCLUSION Aseptic processing is the method of packaging food products in sterile containers to maintain their quality. The global aseptic processing market is estimated to grow exponentially owing to the rising demand for efficient packaging of food products. Moreover, the rapidly expanding packaging industry, new technological advancements, and the proliferation in the pharmaceuticals sector are also expected to contribute to the market’s growth.
Significant COVID-19 Impact on Additive Manufacturing in Pharmaceutical Industry | Data Bridge Market Research
COVID-19 Impact on Additive Manufacturing in Pharmaceutical Industry The outbreak of Coronavirus has caused many industries to change the way they operate, and manufacturing industry is no exception. Also, the rise in demand of antiviral drugs was observed along with decrease in demand of drugs for other ailments. The European Fine Chemical Group estimated that 80% and upward of chemicals used in the making pharmaceuticals sold in the Europe region originate from China and India. Everyday millions of patients rely on drugs manufactured and supplied by pharmaceutical industries; shortage of any particular medicine may create chaos. Manufacturers served throughout the pandemic and are still operating to prevent such turmoil. PRICE IMPACT Throughout year 2020 the COVID-19 pandemic caused economic turmoil globally, the pharmaceutical industry in particular had to adapt quickly to minimize the impact on its operations and supply chain of drugs worldwide. Raw materials and additives rates have increased due to reduced supplies and delayed manufacturing plans, and shut downs in some countries. The price of additives and raw materials has increased during the COVID-19 pandemic due to numerous air travel restrictions and inefficiency to supply products. For instance, · The shortage has begun to affect API and bulk prices in trades, the average increase in India was reported to be about 10-15%, and is estimated to reach 50% in some cases. · WACKER Chemie AG a Germany based company is about to raise its prices for dispersions and solid resins in Europe, Africa and Middle East region stating that this measure has been necessitated by rise in price of raw materials cost in market. · The Edelweiss Securities predicted that COVID-19 pandemic would cause severe supply disruptions in pharma sectors causing earing cuts by 15%. But globally pharma companies are performing well, in short term most companies are expected to bounce back in five years. This thus signifies that due to COVID-19 pandemic the price of additives used in pharmaceutical productions have increased due to Coronavirus outspread. IMPACT ON DEMAND The Coronavirus led to the widespread closure of local manufacturing plants and companies and has badly affected the various region of world. Due to extensive lockdown and isolation the economic activity has affected adversely which has impacted the global economic activity. Manufacturers began to diversify sourcing of raw materials along with investment in spreading production in different regional markets instead of concentrated markets such as India and China. Likely to be long term effect is reindustrialization of pharmaceutical production in countries such as the United States and Europe in order to minimize dependency on imported products, this would lead to rise in demand of additives in above mentioned countries. Moreover the increasing cases of COVID-19 have also paved the way for enhanced demand of additives but due to movement restrictions same decrease in sales was recorded. For instance, · In January 2021, BASF SE had no indication of any major effect on the global activities and supply chain of our BASF Nutrition & Health sector comprising of BASF Pharma Solutions, BASF Animal Nutrition, BASF Human Nutrition, BASF Enzymes and BASF Fragrance Ingredients owing to the COVID-19 pandemic. · In 2020, DuPont de Nemours, Inc. recorded decrease in earning of excipients sales, which belonged to Nutrition and Biosciences segment. This thus signifies that increasing prevalence of COVID-19 poses a life threatening effect to various types of patients already suffering from several kinds of disease among the most recent known COVID-19 pandemic. Thus the demand of effective treatment option that is antiviral drug has enhanced the supply for short term. This thus demonstrates that COVID-19 is accelerating the demand of additive market. IMPACT ON SUPPLY As COVID-19 spreading began in China the surge of medicines has been enhanced due to increasing patient’s volume which put a pressure over the supply of pharmaceutical additives. Moreover the COVID-19 pandemic has changed the business environment for more organizations across the globe. Around the world many companies are hugely reliant on supplies and production in China. However the market players are adopting several initiatives in order to maintain a continuous supply of additives. For instance, · As per the news of September, 2020 this has been suggested that Sandoz is working closely with the Association for Accessible Medicines in order to enhance the global pharmaceutical supply chain. · In 2020, Ashland which is an essential supplier, their supply chain continued to operate safely receive, process and ship specialty products during COVID-19. · As per November 2020 Merck KGaA a company specialized in additives and chemicals stated that it continued to leverage their business continuity plans including risk mitigation activities, accelerated investments and adjusted production schedules for few high demand products. · According to the news of March 2020, Roquette Frères stated that they are working in order to minimize the COVID-19 impact on its supply chain. · As per February 2020, FDA closely monitored supply chain with the possibility of potential disruptions in supply of critical medical products in the U.S. Manufacturers alerted FDA about recently added drugs in drugs shortage list. · DFE Pharma claims that their continued production and supply during the pandemic was not affected in Netherlands, India, Germany and New Zealand. Apparently due to COVID-19 effects on global transport industry the shipping companies are charging more than usual. This suggests that increasing prevalence of COVID-19 poses threat for maintaining a continuous supply chain of additives while initiative adopted by market players allows them to manage a continuous supply chain. STRATEGIC DECISIONS OF MANUFACTURERS Strategic initiatives by market players such as Dow, Ashland, Kerry, BASF SE among others in the market will help them to expand their network and supply chain. This in turn will lead to increasing product sales and hence will enhance the overall company’s revenue. Additive manufacturing companies are taking so many strategic decisions in order to cope up with the current scenario of COVID-19 pandemic. The companies engaged in manufacturing of additive manufacturers are collaborating so as to accelerate the market growth. Companies have already taken several kinds of strategic initiatives in order to cope up with the Coronavirus situation. For instance, · In May 2020, Dow during the COVID-19 pandemic was working closely with government officials and medical professionals, using guidance to adjust plans as warranted. · In April 2020, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) published guidelines on Exceptional GMP flexibilities which allow manufacturers to increase their production capability to minimize risk of product shortage using quality risk management principles and to navigate through international travel restrictions imposed due to COVID-19. · In April 2020, Lubrizol enabled 1 Billion bottles of hand sanitizer globally every month to increase its Carbopol polymer production, which is used as a thickener. The increasing demand and sales of antiviral drugs are fuelling the growth of additive manufacturing in pharmaceutical market. Thus, companies operating in the additive manufacturing in pharmaceutical market are adopting several strategies, including agreements, market expansion to enhance their business. These strategic decisions by the market players helped them to attain a lucrative growth even during the COVID-19 pandemic. CONCLUSION As the pandemic of COVID-19 has resulted in several restrictions throughout the borders but still manufacturers of additive manufacturing in pharmaceutical are able to manage their stocks. The demand and supply of pharmaceutical products increased rapidly due to given medical emergency. Various manufacturers are continuously engaging in constantly monitoring the supply chain so as to attain a lucrative growth. The activities and certain changes from COVID-19 would reduce dependency of private pharmaceuticals on alone suppliers such as China. Drug shortage caused due to the pandemic is expected to remain limited this way for a short period, also if the pandemic exceeds the shortage of pharmaceutical APIs, chemicals and additives may persist on causing shortage of supply in long run. This would also effect complications in distribution especially due to population movement restrictions across the globe.
Let’s Unveil the Surprising Connectivity between Binge Eating and Binge Drinking Disorder
Binge eating and binge drinking problem are pretty common these days. According to a research study by the National Institute of Mental Health, people with binge eating and binge drinking disorder are badly engaged in alcohol consumption. Also, comorbidity is an amalgamation of genetics, impulsivity issues, and a wish to get away from negative thoughts. Before we unveil every minor detail about these frightening disorders, let's introduce both of these concepts briefly. Concept of Binge Eating and Binge Drinking Binge is defined as the period of unrestrained or extreme indulgence, and it mainly describes overconsumption of food and alcohol. Recent researchers explore that around 25% of college-age women have binge eating problems. Sadly, more than 10% to 15% of women binge eat every week. The problem isn't common among women only as 42% of the college students (including boys and girls) have this problem of excess eating. Binge drinking is a state of continuous consumption of alcoholic beverages in a limited time. Again, more than 40% of college students are involved in binge consumption of the alcoholic beverage. Putting in a nutshell, both of these disorders associate exigency and neuroticism. Is There Any Way To Get Away From Binge Eating And Binge Drinking? As discussed earlier, more than 40% of people with binge disorder consume alcohol excessively. The research analysis of the National Eating Disorder Association clearly states that people with binge or purge consume alcohol five times more than people with restrictive type eating disorder. So, there is a clear correlation between binge and purge. Both of these disorders have a significant association with each other, but they have some substantial differences. Binge eating disorder (BED) is common in the U.S. as more than 4% of women and 2% of men have this illness. Similarly, U.S. is the leading country where adults are addicted to binge alcohol consumption, and this frightening percentage is increasing drastically. Here is a list of some impressive ways to get away from both of these disorders. 1. Trench your diet 2. Don’t skip your meal 3. Try mindful meditations 4. Drink enough water 5. Practice Yoga 6. Consume excess fiber 7. Avoid eating junk food 8. Go to the gym 9. Don’t skip your breakfast 10. Sleep for 7 to 9 hours regularly 11. Track your eating pattern 12. Share your feelings with a trustworthy person 13. Eat more protein 14. Plan healthy meals 15. Seek professional help Undoubtedly, the above-mentioned ways can be implemented quickly. We understand you can't escape from these disorders in a blink of an eye but seeking professional help always yields positive outcomes. That's why; it is necessary to choose the renowned and well-reputed mental health clinic near to your location. No denial, the expert and competent mental health specialist understands your problem and suggests the ideal strategies to eliminate a mental disorder successfully. Remember, it takes time to get away from mental health problems, so have some patience and faith in your specialist. Now, let’s come back to the original discussion. Do These Disorders Co-Exist? It's a million-dollar question to contemplate, i.e., 'is there any connectivity between both of these disorders?' Well, two prevailing theories mention that both of these disorders co-exist in an individual. Moreover, the studies also unveil that these orders are standard among women than men. According to the first theory, binge eating and excess alcohol consumption share parallel gratifying properties among depressed, anxious and sad people. According to the second theory, both disorders provide temporary relief to individuals for negative thoughts and emotions. Precisely, both of these disorders are sedating, and people over-consume and over-drink to get rid of depression, anxiety, and negative thoughts. Case Study of ‘Maria’ With Binge Eating Disorder Maria, A 38 years old divorced woman with a successful career, started overeating after a sexual assault in her college life. Due to hypertension and anxiety, she couldn’t control her diet. Resultantly, her weight increased from 135 lbs to 160lbs. primarily, she started binge eating in her college life due to a stressful situation. Currently, she is getting treatment for cholesterol and hypertension, but she feels pain in the knee due to excess weight. Here are some common symptoms of binge eating disorder in her; 1. Overweight/Obesity 2. Excess Eating 3. Trauma Common Diagnosis and Treatments for These Disorders Here are some common treatments for both of these disorders; ü Cognitive Behavioral Therapy ü Interpersonal Psychotherapy Eating and Drinking Disorders Are Mental Illnesses, Not Lifestyle Choices Undoubtedly, it is somewhat challenging to control these disorders because they are irrepressible, uncontrollable, and repressive. So, don't feel guilt or shame as these mental health issues can be treated. Instead of staying alone and isolated, seeking professional help and spending a healthy life is better.
COVID-19 Impact on Warts Treatment in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Warts Treatment in Healthcare Industry COVID-19 spread cursorily across the various countries of the globe, with high number of cases reported worldwide. We can see the impact of COVID-19 on global economy. The COVID-19 has given rise to many complex challenges in the front of different health care companies which has badly influenced the global economy. The first case of COVID-19 was reported in the city of Wuhan, China from where it has speeded every region of the world and become pandemic for world. This pandemic situation has badly affected healthcare companies and pharmaceutical sector. COVID-19 also affected the market by influencing price of warts treatment, demand and supply of warts treatment products and various strategic decisions taken by manufacturers of warts treatment products. Warts are common skin growths caused by a virus human papillomavirus (HPV). They are not cancer and don’t turn into cancer. Warts can spread to other people and other part of body by come in contact. PRICE IMPACT During COVID-19, the need for successful treatment of different types of skin disorders such as warts is rising due to people's fear of COVID-19 infection. The price of drugs used in treatment of warts increased during the COVID-19. Price of drug Leflunomide increased during pandemic because this drug is used for both COVID-19 infection and for warts treatment due to its immunosuppressive and antiviral activity. Leflunomide is a potential option for post transplantation patients with skin warts and small-scale medication of Leflunomide is also used in treatment of COVID-19. For instance, · Cryotherapy with liquid nitrogen is one of very effective treatment of warts. The cure rates of 50 to 70% after three or four treatments. Due to spread of COVID-19 there is variation in rate of cryotherapy. Now the rate of cryotherapy increased to USD 60 to USD 100 for single session from USD 30 for one session. · Pulsed dry laser is a laser treatment used for the treat warts. There is variation in the price of pulsed dry laser treatment due to spread of COVID-19. The price of pulsed dry laser increased to average cost of USD 725 for on session from USD 500 per session. IMPACT ON DEMAND COVID-19 has led to the closure of many manufacturing plants and companies of various region of world. Due to closure of manufacturing plants in various regions the global economy has very badly affected. COVID 19 is expected to be opportunity for the markets. Because many immunosuppressive drugs such as Leflunomide are used for treatment of both post transplantation patients with skin warts and Coronavirus due to its immunosuppressive and antiviral activity. Due to this the demand of warts treatment is increased. FIGURE 1. PREVALENCE OF WARTS TREATMENT chart shows that there is increase in prevalence of wart in year 2020 as compare to number of prevalence in last year 2019. This increase in prevalence shows that there is increase in demand of wart treatment product as compared to last year. For instance, · As we know that wart is define as common skin disorder caused by human papillomavirus (HPV). It spread from one part of body to other part and one person to other person by come in contact. It has been estimated that 70% of sexually active women become infected during their life time with human papillomavirus (HPV) · According to Peritech Pharma, it is estimated that only up to 5% of HPV carriers develop genital warts. 45% of genital warts patients are belonging to age group of 14 and 19. This directly led to increase in demand of wart treatment. IMPACT ON SUPPLY As COVID-19 spreading began in China and China is world supplier of raw material for the production of various pharmaceutical products. Due to spread of COVID-19 lockdown have imposed by government of various countries. There are restrictions on cross country transportation such as air freights ban across the globe. The transportation restrictions have direct impact on supply chain. This led to a decrease in supply of APIs needed for drug manufacturing. This shortage of API also led to increase in price and demand raw material. These shortages also act as great opportunity for many domestic companies for increasing the sale of their products and become leader of respective market. For instance, · Due to spread of COVID-19 we have to face health crisis and an economic disaster across the world. Since the manufacturing activities in China and India shut down. One of major reason of shut down of manufacturing activities in India is the shortage of raw material or APIs which are majorly supplied from the Chine to all over the world. This led to increase in price and demand of many pharmaceutical products. · Due to spread of COVID-19 there are restrictions in manufacturing and logistic activities have been suspended. In order to satisfy the need for food grains, ingredients, medication and other important products, an action plan to counter pandemic-based disturbances has been proposed. STRATEGIC DECISIONS OF MANUFACTURERS Collaboration, agreements, strategic initiatives by market players such as Cutanea Life Sciences, Inc, Verrica, Merck & Co., Inc, Cassiopea, Bausch Health Companies Inc among others in the market will help them to expand their product portfolio. This in turn will lead to increasing product sales and hence will enhance the overall company’s revenue. Major players of the market companies are taking many decisions in order to cope up with the current scenario of COVID-19 pandemic. The companies engaged in manufacturing of wart treatment products are collaborating so as to accelerate the market growth. Companies have already taken several kinds of strategic initiatives in order to cope up with the Coronavirus situation. For instance, · In August 2019, Cutanea Life Sciences, Inc is developing CLS001 for the treatment of common warts. CLS001 is currently in phase III trial. If trial successful, it will most awaited treatment options for the patients with warts. · In June 2019, Verrica Pharmaceuticals reported positive topline results from phase II, open label clinical trial (COVE-1) for VP-102 to be developed for the treatment of common warts. · In July 2018, Cassiopea announced the availability of proof of concept for their Phase II clinical trial being conducted for "CB-06-02" topical 15% immune modulator tellurium-based gel designed for the treatment of genital warts at an extreme level. · In June 2018, Merck & Co., Inc. announced that they had received the U.S. FDA approval for the new supplemental review submitted by the company of a supplemental Biologics License Application for “GARDASIL”, 9-valent HPV vaccine. The review is for expansion of age indication of the drug covering nine HPV types and their treatment. · In February 2020, Bausch Health Companies Inc. launched a new telemedicine platform on Dermatology. Com in the U.S. This website allows patients to consult with a healthcare professional in order to receive prescription on demand for various dermatology products such as ALDARA, SOLODYN. CONCLUSION The pandemic of COVID-19 has resulted in several restrictions throughout the borders. There is great economical unbalance throughout the world. Many segments have to face economic crises, but still manufacturers of warts treatment products are able to manage their stocks. Various manufacturers are continuously engage in conducting clinical trials for demonstrating the safety and efficacy of warts treatment along with this they are constantly monitoring the supply chain so as to attain a lucrative growth. Rise in price is also beneficial for companies. They are gaining extra profit which is helping them to combat the negative effect on overall revenue.
COVID-19 Impact on Global Thoracic Surgery Devices Market in Healthcare Industry | Data Bridge Market Research
COVID-19 Impact on Global Thoracic Surgery Devices Market in Healthcare Industry The COVID-19 pandemic has gripped every nation's health care system and provisions on all levels. It is a respiratory disease which is caused by SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2). The first case of COVID-19 can be traced back to November, 2019 in China weeks before the authorities announced the emergence of the new virus. The virus has affected all regions such as North America, Europe, Asia-Pacific, South America and Middle East and Africa. There is no region that is not affected by the virus. In March, the World Health Organization (WHO) declared COVID-19 as a pandemic referring to more than 118,000 cases of coronavirus disease in more than 110 countries and territories worldwide and the continuing possibility of further global spread. While some countries have struggled to respond to the pandemic, others have faced the challenge far more effectively. The highest number of new confirmed cases globally was reported in December, 2020 (1,771,180). Countries such as the U.S., Brazil and Mexico were at the top with the highest death toll. The pandemic has particularly impacted the field of thoracic surgery with elective (or cases which do not require immediate attention) operation being delayed while in some regions being halted. Certain clinical staffs have been asked to stay at home, there has been re-distribution of the clinical workforce to attend the COVID-19 patients causing disruption in normal public services affecting the healthcare workforce. As a result, the impact is noticeable in the thoracic surgery devices market. Surgery on the organs in the chest or thorax requires thoracic surgery. The food pipe, wind pipe, lungs, chest wall, heart and diaphragm are among the most popular treatments. Thoracic surgery is frequently associated with heart surgery and is known as cardiothoracic surgery. The aim of thoracic surgery is to treat organs in the chest or thorax that are diseased or damaged. IMPACT ON SUPPLY The pandemic has triggered unprecedented increased demand for certain medical devices while significant disruption to manufacturing and supply chain of various others. The pandemic forced various countries to go into lockdown which also disrupted the supply chain of several raw materials and components for certain surgical medical devices including the devices used for thoracic surgeries. For instance, · In March 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law. The CARES Act added Section 506J to the Federal Food, Drug and Cosmetic Act (FD&C Act) and provided the FDA for the first time with new authority that intended to help prevent or mitigate negative public health impacts of medical devices supply chain disruptions “during or in advance of a public health emergency declared by the Secretary under section 319 of the Public Health Service (PHS) Act.” The creation of the law leads to the allowance of thoracic surgeries which was life threatening or of the utmost importance to be conducted while the patients who had to undergo thoracic surgeries to get an approval and the rest (unimportant as per the situation) were delayed indefinitely. This has slowed down the supply of thoracic surgery devices market. However, the launch of new products and new acquisitions by the companies intend to increase the supply of the thoracic surgery devices market. · In December 2020, A&E Medical Corp., a cardiothoracic surgery business was acquired by Zimmer Biomet. USD 150.00 million cash at closing and USD 100.00 million cash payable this year which is included in the USD 250.00 million deals. In the dental, spinal and craniomaxillofacial and thoracic business unit of Zimmer Biomet, revenues from the portfolio will be remembered. This is intended to improve the availability of instruments for thoracic surgery. · In September 2020, Ethicon, a part of Johnson & Johnson Medical Devices Companies announced the introduction of ECHELON ENDOPATH Staple Line Reinforcement (SLR), a new buttressing system designed to further reinforce staple lines and reduce possible complications during bariatric, thoracic and general surgical procedures. This is the company's first buttress solution designed for use with its own industry-leading GST reloaded ECHELON FLEX Driven Staplers which have been connected to lower air leakage rates and bleeding complications. ECHELON ENDOPATH SLR is to assist surgeons who want even more power along the staple line and to solve problems with current buttressing options that can be hard to load and result in uneven coverage of the staple line that can loosen during stapling procedures with traditional manoeuvring. IMPACT ON DEMAND The complications of the virus reach well beyond respiratory failure to life-threatening cardiac, renal and immunological dysfunction to name a few. The consequences have been profound for cardiac surgery and cardiac surgeons. Although they are not as involved as the front-line warriors, they have been called upon to provide the local healthcare providers who have navigated the various challenges posed by the virus with leadership and direction. Due to their engagement in the prevention of the on-going pandemic, the demand for the thoracic surgery devices were reduced. Though, the growing demand for cardiovascular surgeries which are driven by factors which include the increase in the cardiac rhythm management (CRM) system replacements, the increasing number of CRM implantation facilities and also the rising popularity of CVD and lung diseases. For instance · In North America, the numbers of cardiovascular surgeries are predicted to rise to 461,046 in 2021. · In January 2021, King George’s Medical University (KGMU) became the countries third dedicated thoracic surgery department. This would eventually boost the demand for thoracic surgery devices in the upcoming years. · Due to technical advancement, improved surgical experience and confidence among high-risk individuals, the demand for thoracic surgery has also increased among older patients and patients with significant co-morbidities. It is also expected that the growth in demand for minimal invasive thoracic procedures would drive the market. · The cancellation of all surgeries except those deemed essential to minimize contact between patients and physicians caused a decline in the surgical practices during the pandemic which in-turn increased the demand for video-assisted thoracoscopic surgeries (VATS). · The high prevalence of lung cancer is likely to boost the global thoracic surgery devices market. Lung cancer is the second-most common type of cancer. According to the estimation of American Cancer Society, around 228,150 new cases of lung cancer are reported in 2019. CONCLUSION COVID-19 has created havoc causing drastic changes in the healthcare sector. However, due to the new law added by the CARES Act, the thoracic surgery devices market had come to a halt. But the thoracic surgery devices market is expected to boom in the coming years majorly due to the increase in cardiovascular surgeries, high prevalence of lung diseases and rise in the number of people opting for VATS.